Pharmaceutics_R&D
Follow
3.5K views | +16 today
Scooped by Julien Hering, PhD
onto Pharmaceutics_R&D
Scoop.it!

Pioneering study will test if trio of Roche, Lilly drugs can prevent Alzheimer's

Pioneering study will test if trio of Roche, Lilly drugs can prevent Alzheimer's | Pharmaceutics_R&D | Scoop.it

Washington University School of Medicine in St. Louis has pieced together a pioneering new study that will help put a new theory on preventing Alzheimer's to a definitive test.  - FierceBiotech | October 10, 2012 | By John Carroll

more...
No comment yet.
Pharmaceutics_R&D
Pharmaceutical companies R&D specifically in neuroscience, CNS disease, pain and electrophysiology
Your new post is loading...
Scooped by Julien Hering, PhD
Scoop.it!

Why pharma need to build internal digital capabilities

Why pharma need to build internal digital capabilities | Pharmaceutics_R&D | Scoop.it

It's becoming essential that pharma embrace digital transformation urgently to survive, but the challenge companies face is knowing how and where to begin.

The pharmaceutical industry is currently facing a time of unprecedented change. Coming fast on the heels of the recent economic recession, the new digital economy is reshaping the way we do business. Technology now has a huge influence over business growth and capability, and the time for resisting is rapidly reaching an end. Big pharma has typically been slow to accept change, partly because of a conservative culture and partly because of fear of regulatory consequences. (...) - by Ash Rshi, March 13, 2014

Julien Hering, PhD's insight:

Digital transformation for big pharma at all levels : marketing, medical affairs... but also in R&D, virtual teams, and e-health! 

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

PharmaGossip: Lilly depression drug fails late-stage trial

Eli Lilly and Co on Thursday said its experimental drug to treat major depression failed to meet it primary goal in three late-stage trials and the drugmaker will not seek approval of the medicine for that condition.

The drug edivoxetine, a member of a family of medicines called norepinephrine reuptake inhibitors, was tested in combination with a member of a widely used class of depression treatments called selective serotonin reuptake inhibitors (SSRIs) in each of the three trials.

But after eight weeks of treatment, the combination of drugs that included edivoxetine did not prove superior to the SSRIs alone, thereby failing the main goal of the study. - PharmaGossip, December 5, 2013

more...
No comment yet.
Suggested by Magali Michel
Scoop.it!

"Dans l’industrie pharmaceutique, l'innovation génère un changement dans la proposition de valeur"

"Dans l’industrie pharmaceutique, l'innovation génère un changement dans la proposition de valeur" | Pharmaceutics_R&D | Scoop.it

Un rythme d’innovation accéléré, de nouveaux business models... L’industrie pharmaceutique n’est pas, comme les autres secteurs, épargné par la nécessité de s’adapter au renouveau technologique. (...) - par Quentin Capelle, L'Atelier Disruptive Innovation, 14 octobre 2013 

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Top 25 Biotech Companies of 2013

Top 25 Biotech Companies of 2013 | Pharmaceutics_R&D | Scoop.it

A list of 25 biotech companies, ranked by their market capitalization for the latest quarter that they furnished figures on their numbers of outstanding shares.


Last year, GEN published a list of the top 25 biotech companies. So, who would make the list this year? Find out by checking out this updated list of 25 biotech companies ranked by their market capitalization for the latest quarter that they furnished figures on their numbers of outstanding shares.

Overall, the past year has been mostly very good to biotechs where market cap is concerned, the result of a stock market surge that has not only lifted prices well into double-digits for most of the companies on the list, but also finally jumpstarted the market for initial public offerings after several years of spinning its wheels. (...) Genetic Engineering & Biotechnology ews, July 22, 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Plombée en France, l’industrie pharmaceutique se lamente toujours

Plombée en France, l’industrie pharmaceutique se lamente toujours | Pharmaceutics_R&D | Scoop.it

En croissance grâce à ses exportations, l’industrie du médicament voit son marché français chuter. Et se dit victime des plans d’économies pour la sécurité sociale et de multiples taxes. Alors même qu’un député veut lui en imposer une nouvelle, pour la recherche dans le cancer des enfants… (...) - L'Usine Nouvelle, 14/06/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

European Court Wants Drug Data Kept Secret

 A court has ordered the European Medicines Agency (EMA) to keep data from two drug companies confidential, running counter to EMA's recent push to share clinical and nonclinical information as widely as possible. The temporary injunction from the General Court of the European Union backs two drug firms on the U.S. side of the pond: AbbVie, headquartered in North Chicago, Illinois, and InterMune in Brisbane, California. (...) - ScienceInsider, by Jennifer Couzin-Frankel on 30 April 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Tour de France de LaBiotech

Tour de France de LaBiotech | Pharmaceutics_R&D | Scoop.it
Le Tour de France de LaBiotech à vélo vise à réaliser un panorama filmé des entreprises de biotechnologies pour le partager au monde entier.
Nous sommes les co-fondateurs du site LaBiotech.fr qui centralise l’actualité des Biotechnologies tout en créant du contenu exclusif pour vous informer du secteur rapidement, simplement et gratuitement. Lancé en décembre 2012, il rassemble désormais plus de 300 abonnés et 2000 visiteurs uniques.


Avec deux vélos, nos jambes et du soutien, nous souhaitons parcourir la France pour interviewer les différentes entreprises des Biotechnologies. Le trajet et les interviews, tous les deux filmés, seront rassemblés dans un documentaire sous-titré en anglais, allemand et espagnol. Le but étant d'établir un panorama du secteur des biotechnologies françaises et de le partager gratuitement avec le monde entier.


Le Tour débutera par un prologue en Ile de France du 1er au 12 juillet et partira de Paris le dimanche 14 juillet jusqu'au vendredi 2 aout. Les grandes destinations seront Strasbourg, puis Lyon, Marseille, Bordeaux et Nantes. Pour réaliser ce tour, nous avons besoin d'un budget de 4000€ composé de matériel photo/vidéo, de matériel vélo et des frais de déplacement. Nous avons besoin de vous pour nous aider et permettre de réaliser cette expérience qui sera positive pour le secteur des biotechnologies françaises ainsi que pour la France.


Ce projet vous plait ? Alors suivez-nous, partagez-nous et soutenez-nous !

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

L'irrésistible déclin de l’industrie pharmaceutique en France

L'irrésistible déclin de l’industrie pharmaceutique en France | Pharmaceutics_R&D | Scoop.it

Baisses de prix, impact des génériques : le marché du médicament devrait continuer de décliner cette année en France, selon une étude d’IMS Health. Une embellie serait possible en 2014, en fonction des décisions politiques.


Alors que les plans sociaux se poursuivent dans l’industrie pharmaceutique, les perspectives sur le marché français sont toujours sombres. Après avoir connu la première récession de son histoire en 2012, avec une chute de 2,3% en valeur, le marché des médicaments en ville devrait s’effondrer de 3,4% cette année, selon l’étude présentée ce mardi par le cabinet de conseil pour les acteurs de la santé IMS Health. (...) L'Usine Nouvelle, par Gaëlle Fleitour19 mars 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

» Troubles bipolaires: AstraZeneca lance Bipolife®, un outil inédit pour les malades et leur entourage

» Troubles bipolaires: AstraZeneca lance Bipolife®, un outil inédit pour les malades et leur entourage | Pharmaceutics_R&D | Scoop.it

AstraZeneca a lancé Bipolife® : le premier outil interactif à visée psychoéducative spécifiquement dédié aux troubles bipolaires. Développé en collaboration avec l’entreprise Ubisoft et sous la supervision d’un comité scientifique, Bipolife® a pour objectif d’aider les personnes souffrant de troubles bipolaires à mieux comprendre leur maladie et à identifier les comportements quotidiens qui influent sur son évolution. (...) - MyPharma, 01/04/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Why all pharmaceutical research should be made open access

Why all pharmaceutical research should be made open access | Pharmaceutics_R&D | Scoop.it

The government wants to make all publicly funded research available – but the same must be demanded of pharmas also

I recently had lunch with as staunch an advocate for open access as you'll ever meet (I won't name him, because it would be rude to attribute casual remarks to him without permission). We were talking about plans to mandate free and open publication of publicly funded scientific research. In the USA, there's the Federal Public Research Act, and in the UK, there's the coalition government's announcement that publicly funded research should be made available at no cost, under a Creative Commons licence that permits unlimited copying. (...) by Cory Doctorow, The Guardian, 20 november 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation - GaBI Journal

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation - GaBI Journal | Pharmaceutics_R&D | Scoop.it

Background: Due to the declining innovativeness of the classic R & D model in the original pharmaceutical industry, the generic pharmaceutical industry is aiming to become an innovation generator itself. 

Results: Those generic pharmaceutical firms that implement new competitive strategies have integrated re-innovation design into their product portfolio to provide more personalized, cost-effective products to meet the healthcare systems’, policymakers’ and patients’ demand for high quality accessible treatments. This re-orientation hopes to better face the changing competition challenges in both mature and developing markets. 
Conclusions: A new approach to innovativeness together with a value proposition strategy aims to deliver high quality products to patients.

(...) - by Barei F. et al., Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1)


more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

4 Key Drug Approvals Expected In The Next 30 Days

4 Key Drug Approvals Expected In The Next 30 Days | Pharmaceutics_R&D | Scoop.it

Biogen Idec's BG-12, United Therapeutics' oral Remodulin, Johnson & Johnson's Invokana and Allergan's Levadex are all nearing their possible launches

Investing in drug stocks isn't quite like investing in other stocks. While drugmakers' shares can move on earnings and buyout news like anyone else's, what really gets investors excited is an FDA decision allowing a new drug on the market. Here are some of the most important drugs awaiting approval in the next month. (...) - by Amy Reeves, Investors.com, 03/15/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Réputation des Big Pharma américaines

Parmi les Big Pharma, Johson&Johson est la seule survivante dans le TOP60 des « most visible companies » établi tous les ans par Harris, avec une excellente 5e place.
Pfizer n’y figure plus depuis 2 ans.
Globalement, l’industrie pharmaceutique a un rating négatif à 40%.
à noter que Facebook n’occupe qu’une modeste 42e place, loin derrière Amazon (1er), Apple (2e) et Google (4e) (...) - Blog "Intelligene scientifique & veille", 14/02/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Le groupe pharmaceutique GSK s'impose des pratiques plus éthiques

Le groupe pharmaceutique GSK s'impose des pratiques plus éthiques | Pharmaceutics_R&D | Scoop.it

Le britannique cesse de rémunérer les médecins pour la promotion de ses produits.
L'industrie pharmaceutique serait-elle prête à faire sa révolution culturelle ? En réformant ses pratiques commerciales, le britannique GSK donne en tout cas un signal dans ce sens. (...) - par Catherine Ducruet, Les Echos, 18/12/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Novartis reboots brain division

Novartis reboots brain division | Pharmaceutics_R&D | Scoop.it
After years in the doldrums, research into neurological disorders is about to undergo a major change of direction.

In a sign that psychiatric-disease research is entering a new era, the pharmaceutical giant Novartis has hired an expert in neural circuitry, rather than pharmacology, to head its relaunched neuroscience division. (...) - by Alison Abbot, Nature, 08 October 2013

more...
Magdalena Kawalec's curator insight, November 25, 2013 7:01 AM

Good decission. Befor to decide "how to design it" maybe better to know "how it works in the first place"

Scooped by Julien Hering, PhD
Scoop.it!

Advertisements impact the physiological efficacy of a branded drug

We conducted randomized clinical trials to examine the impact of direct-to-consumer advertisements on the efficacy of a branded drug. We compared the objectively measured, physiological effect of Claritin (Merck & Co.), a leading antihistamine medication, across subjects randomized to watch a movie spliced with advertisements for Claritin or advertisements for Zyrtec (McNeil), a competitor antihistamine. Among subjects who test negative for common allergies, exposure to Claritin advertisements rather than Zyrtec advertisements increases the efficacy of Claritin. We conclude that branded drugs can interact with exposure to television advertisements. (...) - by Kamenica E et al., PNAS August 6, 2013 vol. 110 no. 32 12931-12935

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease

Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease | Pharmaceutics_R&D | Scoop.it

Neurotrophins and their receptors modulate multiple signalling pathways to regulate neuronal survival and to maintain axonal and dendritic networks and synaptic plasticity. Neurotrophins have potential for the treatment of neurological diseases. However, their therapeutic application has been limited owing to their poor plasma stability, restricted nervous system penetration and, importantly, the pleiotropic actions that derive from their concomitant binding to multiple receptors. One strategy to overcome these limitations is to target individual neurotrophin receptors — such as tropomyosin receptor kinase A (TRKA), TRKB, TRKC, the p75 neurotrophin receptor or sortilin — with small-molecule ligands. Such small molecules might also modulate various aspects of these signalling pathways in ways that are distinct from the programmes triggered by native neurotrophins. By departing from conventional neurotrophin signalling, these ligands might provide novel therapeutic options for a broad range of neurological indications. (...) - by Frank M. Longo Stephen M. MassaNature Reviews Drug Discovery 12, 507–525 (2013)

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Does pharma spend more on marketing than R&D? A numbers check

Does pharma spend more on marketing than R&D? A numbers check | Pharmaceutics_R&D | Scoop.it

So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.

Derek Lowe's blog dug up the numbers and calculated spending as a percentage of revenue. In the case of R&D, that's pretty easy to determine; companies break that number out as its own line item. As for marketing, sales expenses are lumped into a category dubbed SG&A, or sales, general and administrative expenses. And as Lowe notes, that category includes lots more than sales spending. Executive salaries, for instance. (...) - by Tracy Staton, FiercePharma, May 21, 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Target identification and mechanism of action in chemical biology and drug discovery

Target identification and mechanism of action in chemical biology and drug discovery | Pharmaceutics_R&D | Scoop.it

Target-identification and mechanism-of-action studies have important roles in small-molecule probe and drug discovery. Biological and technological advances have resulted in the increasing use of cell-based assays to discover new biologically active small molecules. Such studies allow small-molecule action to be tested in a more disease-relevant setting at the outset, but they require follow-up studies to determine the precise protein target or targets responsible for the observed phenotype. Target identification can be approached by direct biochemical methods, genetic interactions or computational inference. In many cases, however, combinations of approaches may be required to fully characterize on-target and off-target effects and to understand mechanisms of small-molecule action. (...) - by Schenone M et al., Nature Chemical Biology 9, 232–240 (2013)

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Influence Scores of the 24 Largest Biotech, Pharma, and Medtech Companies - Who’s the winner and how do you fare?

Influence Scores of the 24 Largest Biotech, Pharma, and Medtech Companies - Who’s the winner and how do you fare? | Pharmaceutics_R&D | Scoop.it

Which company takes the title? It may come as no surprise that pharma giant Pfizer claims the lead spot, however the sequence that follows shows interesting trends. In this article I’ll share bioscience companies with ideal digital presence and touch on available apps to score yours. The performance indictor was the Bio Web Score Absolute, a free tool measuring the digital presence of life science businesses. (...) - Biowebspin Public Place, by Sara Ahmadi, 26/04/2013

more...
No comment yet.
Rescooped by Julien Hering, PhD from All about Pharma by Pharmacomptoir
Scoop.it!

Pharma Business

Pharma Business | Pharmaceutics_R&D | Scoop.it

A la recherche du ePatient. (RT @laumacom: A la recherche du ePatient. http://t.co/Nv8KD0FUnr (via @pharmacomptoir) #ePatient #esante)


Via Pharmacomptoir / Corinne Thuderoz
more...
No comment yet.
Rescooped by Julien Hering, PhD from eLearning - entre pedagogies et technologies - between pedagogy et technology
Scoop.it!

Flipped Classrooms: Improved Test Scores and Teacher Satisfaction

Flipped Classrooms: Improved Test Scores and Teacher Satisfaction | Pharmaceutics_R&D | Scoop.it
ClassroomWindow™: Providing an unprecedented view into what works - and for which kids - in U.S. classrooms.
Via Marcel Lebrun
more...
vgpascal's curator insight, April 14, 2013 1:55 AM

Les effets des classés inversées sur l'apprentissage et sur la satisfaction de "donner des occasions d'apprendre" ;-)

Matthieu CLEMENT's comment, April 17, 2013 12:58 AM
Cette méthode marche très bien dans le cadre de l'université. Pour l'avoir testé en classe de seconde en France, c'est beaucoup plus difficile dans le secondaire. http://aggiornamento.hypotheses.org/1238
Bernard Buchel's curator insight, April 21, 2013 7:58 AM

Marcel Lebrun souligne : "De meilleures attitudes des étudiants, des enseignants davantage satisfaits, de meilleurs scores (standardisés) aussi aux évaluations. Pour ce dernier point, tout dépend de ce que l'on "mesure" mais en tout cas, pas de perte dans les connaissances ( les savoirs) contrairement à ce que pourraient penser les grognons. Il faudrait faire de cette méthode une priorité institutionnelle !"

Bref il n'y a pas que les techniques numériques pour renouveler la pédagogie.

Scooped by Julien Hering, PhD
Scoop.it!

Drug-company data vaults to be opened

Drug-company data vaults to be opened | Pharmaceutics_R&D | Scoop.it

European agency will publish firms’ clinical-trial results.


International calls for the pharmaceutical industry to share the results of clinical trials have grown ever more intense amid revelations that high-profile companies have hidden crucial data on safety and efficacy. Now Europe is moving towards measures that would significantly increase disclosure of such data. (...) - by Daniel Cressey, Nature, 27 March 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s | Pharmaceutics_R&D | Scoop.it

US biopharmaceutical companies are currently developing 465 new medicines that target the 10 leading chronic conditions affecting people aged 65 and over, according to new industry data.

The medicines, which are all now in clinical trials or under review by the Food and Drug Administration (FDA), are diverse in scope, notes the Pharmaceutical Research and Manufacturers of America (PhRMA), which has published the data. (...) - by Lynne Taylor, PharmaTimes, March 22, 2013

more...
NCTC's curator insight, March 29, 2013 4:19 AM

Interesting, also in light of the Dutch IEMO project which aims at including seniors in clinical trials to measure the effect durgs have have on them.

Scooped by Julien Hering, PhD
Scoop.it!

AstraZeneca losing 1,600 jobs, with 650 positions cut at U.S. sites

AstraZeneca losing 1,600 jobs, with 650 positions cut at U.S. sites | Pharmaceutics_R&D | Scoop.it

A major reorganization of its research operations will result in 1,600 jobs being cut by AstraZeneca, with roughly 650 positions slashed in the U.S. (...) - By Russ Britt, MarketWatch blog "Health Exchange", March 18, 2013

more...
No comment yet.